This week in Other Barks & Bites: Regulatory hurdles lead Oracle to send a force majeure notice related to its New Mexico data center project; the companion bill for the DEFEND IP Act is introduced into the U.S House of Representatives; the European Union Intellectual Property Office announces the first customs enforcement action on a registered CIGI; the Third Circuit finds no material appropriation of copyrightable elements in a case over allegedly copied curriculum between machine learning professors; and more.
Epiq Counsel is actively seeking a Senior Trademark Paralegal with in-house experience to support a leading global pharmaceutical company. This long-term, Indianapolis-based hybrid opportunity offers the chance to work with a high-performing in-house IP legal team.
Epiq Counsel client, a Fortune 100 pharmaceutical company, is seeking an experienced Patent Paralegal (Global Portfolio | In-House) to support its Intellectual Property team on a hybrid basis (3 days/week onsite) out of their offices in Indianapolis. This long-term, Indianapolis based hybrid opportunity offers the chance to work with a high-performing in-house legal team. The ideal candidate will have experience working with domestic and international patent matters and will serve as a key partner to attorneys, patent professionals, foreign associates, and external vendors.
IPWatchdog has learned that U.S. Patent and Trademark Office (USPTO) Director John Squires plans to celebrate one year in office with an event on September 29. To our knowledge, this is the first time a Director has publicly celebrated the one-year anniversary of their appointment. After the original publication of this article Director Squires took to LinkedIn to claim the story was not properly sourced, focusing only on the location of the event. Squires posted: “I dunno there Gene Quinn, time to invest in a new fact-checker. The event’s being held at Ford’s Theater.” The invitation itself (pictured above) clearly and unambiguously says that the event would take place at the Motion Picture Association headquarters. And whether this event takes place at MPA headquarters or Ford’s Theater, questions still remain about who is paying for the event, whether the event is a public USPTO event, what purpose the event will promote, and whether USPTO employees are planning or executing the event.
This week on IPWatchdog Unleashed, I speak with Martin Correa. Correa, who leads foresight work at the World Intellectual Property Organization (WIPO). Correa’s job is not to predict the future of IP, but to consider what futures are possible so WIPO and Member States can be better prepared for whatever eventuality does materialize. And since there is no data about the future—as he puts it—his work uses signals of change, horizon scanning and competing scenarios to expose assumptions and identify the decisions that could push the IP system in one direction or another.
Patent monetization is often discussed as if the hard part begins when a patent owner makes the decision to license, sell, finance, or enforce its patent assets. That is a mistake and demonstrates a lack of understanding of the difficulties and complexities of patent monetization. By the time a patent owner is sitting across the table from a potential licensee, buyer, lender, litigation funder, or accused infringer, much of the outcome has already been fully determined. The real work begins years earlier in preparation for monetization.
In any patent dispute, the strength of the patent still matters. But increasingly, it is not the only thing that matters—or even, in some cases, the thing that matters most. That means where a patent dispute takes place cannot be a tactical afterthought or viewed as a choice of federal district courts in the United States alone. This is true today more than ever because despite patents ostensibly being property—at least according to the Patent Act—which tribunal and which judges make the ultimate decisions affecting the patent often matter most of all because patents and patent enforcement have become driven by ideology and the type of fervor normally reserved highly emotionally charged discussions, like religion and politics.
President and CEO of the Council for Innovation Promotion (C4IP) and former Acting Director and Deputy Director of the U.S. Patent and Trademark Office (USPTO) Coke Morgan Stewart told attendees of IPWatchdog’s Women’s IP Forum today that “we need to get out the paddles and shock the patient” when it comes to the state of the U.S. patent system.
Biological drugs, or biologics, are now a well-established class of therapeutic products worldwide. Unlike conventional small-molecule drugs, which are generally obtained through chemical synthesis and have relatively simple and well-defined structures, biologics are derived from living organisms or produced through biotechnology processes involving living cells. They include, among others, monoclonal antibodies, recombinant proteins, vaccines, hormones, blood-derived products and advanced cell-based therapies.
Thompson Patent Law is hiring a Patent Attorney for a fully remote position. While we are primarily seeking a full-time hire, we welcome applications from attorneys interested in independent contractor or project-based engagements. This role is designed for an experienced patent attorney who wants consistent, high-quality patent prosecution work, strong internal systems, and a professional environment built around respect, precision, and accountability.
Recent amendments to Federal Rule of Evidence 702 did not invent the trial judge’s gatekeeping obligation, nor did they transform economic analysis. They did, however, sharpen the focus on the burden of establishing admissibility and whether an expert has reliably applied a valid methodology to the facts. Combined with the Federal Circuit’s increasingly demanding review of patent damages opinions, the practical message is unmistakable: the economic case must be engineered from the beginning, or you will surely suffer the consequences only after it is too late.
The mythology surrounding the act of invention tends to concentrate on the breakthrough moment. There is a flash of insight, a sketch is made on a cocktail napkin, the prototype is assembled in a garage to prove the brilliance of the concept. Unfortunately, commercial markets are considerably less romantic. They do not reward ideas merely because they are clever, patentable or even technically superior. They reward products that work, solve a problem customers recognize, can be manufactured at an economically sustainable price and generate an acceptable return for whoever assumes the risk of bringing them to market.
The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a decision today in Dental Monitoring SAS v. Align Technology, Inc., affirming a district court ruling that found several patent claims covering deep learning based dental image analysis invalid as directed to ineligible subject matter under Section 101. Dental Monitoring SAS owns U.S. Patent 11,049,248 and U.S. Patent 10,755,409, both of which relate to dental arch image analysis. The ‘248 patent covers “a method for assessing the shape of an orthodontic aligner using a deep learning device,” while the ‘409 patent covers a method for acquiring and analyzing an image of a dental arch using the same type of device.
This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.
Get Email Updates